Breaking — World-Renowned Vaccinologist Publishes Paper Admitting Lack of Vaccine Safety Studies

In a stunning reversal, Dr. Stanley Plotkin, widely regarded as the godfather of modern vaccinology, has co-authored a paper in the New England Journal of Medicine¹ (NEJM) acknowledging significant gaps in vaccine safety research and calling for increased funding to address these shortcomings.

This admission comes after decades of the medical establishment insisting that vaccines are among the most thoroughly studied and safest medical interventions. In the paper, titled “Funding Postauthorization Vaccine-Safety Science,”² they make a series of revelations that validate concerns long raised by vaccine safety advocates. In a commentary, Aaron Siri, managing partner of New York law firm Siri & Glimstad, writes:³

“Wow. After decades of Dr. Stanley Plotkin and his vaccinologist disciples insisting vaccines are the most well studied products on the planet, they just penned an article admitting precisely the opposite.

They just admitted vaccines are not properly studied — neither prelicensure nor post-licensure. They admitted, for example, ‘prelicensure clinical trials have limited sample sizes [and] follow-up durations’ and that ‘there are not resources earmarked for postauthorization safety studies.'”

Key Admissions Shine Light on Lack of Vaccine Safety Studies

One of the most striking admissions in the paper is the acknowledgment that prelicensure clinical trials for vaccines are inadequate for assessing safety. The authors state:⁴

“Postauthorization studies are needed to fully characterize the safety profile of a new vaccine, since prelicensure clinical trials have limited sample sizes, follow-up durations, and population heterogeneity. It is critical to examine adverse events following immunization (AEFIs) that have not been detected in clinical trials, to ascertain whether they are causally or coincidentally related to vaccination.”

This contradicts previous claims by vaccine proponents that clinical trials provide robust evidence of safety prior to approval. The admission that these trials have limited follow-up periods is particularly notable, as critics have long argued that potential long-term effects of vaccines are not adequately studied before they are approved and recommended for widespread use.

“Let me translate,” Siri writes, “the clinical trials relied upon to license childhood vaccines are useless with regard to safety since they virtually never have a placebo control, typically review safety for days or weeks after injection, and often have far too few participants to measure anything of value.”⁵

The NEJM paper goes on to reveal that there is currently no dedicated funding stream for post-approval vaccine safety studies in the U.S. The authors write: “Although the ACIP [Advisory Committee on Immunization Practices] acknowledges the need, there are currently no resources earmarked for postauthorization safety studies beyond annual appropriations, which must be approved by Congress each year.”⁶

This lack of consistent, dedicated funding is one reason why many important safety questions remain unanswered years or even decades after vaccines have been introduced. The authors admit that “Progress in vaccine-safety science has understandably been slow,” citing delayed epidemiological evidence and incomplete understanding of biological mechanisms as key factors.⁷ But as Siri notes:⁸

“Shameless to pretend you have not for decades ignored or attacked those calling for these studies while pretending a mountain of such studies showing the foregoing don’t already exist … [and] shameless to pretend parent groups have not been yelling about this [funding] issue for decades only to be ignored and attacked.”

‘Not Enough Evidence’ to Determine if 76% of Vaccine-Related Health Outcomes Are Linked to Shots

In a particularly revealing passage, the paper states, “In 234 reviews of various vaccines and health outcomes conducted from 1991 to 2012, the IOM found inadequate evidence to prove or disprove causation in 179 (76%) of the relationships it explored, illustrating the need for more rigorous science.”⁹

This statistic is astounding — for over three-quarters of vaccine-related health outcomes examined by the Institute of Medicine (now the National Academy of Medicine), there was not enough evidence to determine whether vaccines were causally linked or not. This flies in the face of repeated assurances that vaccine safety is settled science.

The paper also notes that even for known adverse reactions to vaccines, the biological mechanisms are not understood. This includes serious conditions like Guillain-Barré syndrome associated with influenza vaccines and myocarditis linked to mRNA COVID-19 shots.

Experts have long been calling for unbiased research in understanding the impact of vaccinations on children’s health, but the reality is that public health agencies and vaccine proponents have not been interested in learning the truth. Siri writes:¹⁰

“If they are really interested in the truth about what injuries vaccines cause and the rate at which these injuries occur, then they should welcome convening a bipartisan panel which could first review all the very concerning studies and hard data that already exists on this topic (often by scientists not on pharma’s dole) and we could design additional studies together and have them run in the open so everybody has to live with the result.

… Plotkin and company should welcome studies which can show vaccines have not contributed to the rise in chronic childhood disease (many of which are immune mediated diseases) from 12% of children in the early 1980s (when CDC recommended 7 routine childhood injections) to over 50% of children now (when CDC recommends over 90 routine childhood injections).

And I think they do welcome such studies if they can assure that the outcome would show vaccines do not cause these harms. Alas, the reality is that (as they know) studies showing vaccines contribute to this rise already exist. But their goal, in any event, is not to really study safety. Rather it is to prove their prior assumption that vaccines are safe and harms are ‘rare.'”

Plotkin and his co-authors, while acknowledging significant gaps in vaccine safety science, propose increased funding by tapping into the Vaccine Injury Compensation Program (VICP) trust fund. They note that this fund, generated by an excise tax on vaccines, has a surplus of $4.3 billion as of April 2023.¹¹